Evidence map›Paper›PMID 30788086›Full record

ArticleJournal of market access & health policy2019

Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective.

Pierre Levy, David Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin, Jean-Baptiste Briere

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of market access & health policy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Pierre LevyDepartment of Economics and Management of Health Organisations, The University of Paris Dauphine, Paris, France.
David SmadjaDepartment of Medicine, The University of Paris Descartes, Paris, France.
Julie DoreyCreativ Ceutical, Paris, France.
Mondher ToumiMedical School, Laboratory of Public Health, The University of the Mediterranean, Marseilles, France.
Anna-Katharina MeineckeBayer AG, Berlin, Germany.
Kevin BowrinBayer Plc, Reading, UK.
Jean-Baptiste BriereBayer AG, Berlin, Germany.
Bayer (Germany) · DEBayer (United Kingdom) · GBCreativ-Ceutical (France) · FRInserm · FRInstitut de Neurobiologie de la Méditerranée · FRUniversité Paris Dauphine-PSL · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Franceinternational normalised ratiomonitoringNonvalvular atrial fibrillationreal-world researchresource use and costsvitamin K antagonists

Identifiers

PMID30788086
PMCPMC6374971
OpenAlexW2913575665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.